ClinConnect ClinConnect Logo
Search / Trial NCT00014989

Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)

Launched by THE GEORGE WASHINGTON UNIVERSITY BIOSTATISTICS CENTER · Apr 17, 2001

Trial Information

Current as of July 23, 2025

Completed

Keywords

Preterm Delivery Cerebral Palsy Magnesium Sulfate

ClinConnect Summary

The prevalence of cerebral palsy is increasing as the survival rate of extremely premature infants is improving. Studies have suggested an apparent association between maternal magnesium sulfate administration and a reduced risk of cerebral palsy. Other studies have suggested a possible association between magnesium sulfate and a reduction in neonatal cranial ultrasound abnormalities which may be markers for subsequent development of cerebral palsy.

This multicenter trial tests whether prophylactic magnesium sulfate given to women, for whom preterm delivery is imminent, reduces the risk of...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Pregnant with diagnosis of preterm labor
  • Membrane rupture or delivery definitely planned within 24 hours
  • Gestational age \> 24.0 and \< 31.6 wks, viable fetus
  • Exclusion Criteria:
  • Prior IV magnesium sulfate therapy within 12 hours of screening
  • Delivery expected \<2 hrs
  • Cervical dilation \> 8 cm
  • More than 2 fetuses
  • Known major fetal anomalies
  • Hypertension or preeclampsia
  • Maternal medical complications contraindicating magnesium sulfate treatment
  • Participation in any intervention study which influences infant neurological outcome
  • Previous participation in this trial

About The George Washington University Biostatistics Center

The George Washington University Biostatistics Center is a leading research institution dedicated to advancing the field of biostatistics through innovative methodologies and rigorous scientific inquiry. As a prominent sponsor of clinical trials, the center specializes in the design, analysis, and interpretation of complex data in health-related research. With a commitment to enhancing public health outcomes, the Biostatistics Center collaborates with academic, governmental, and industry partners to foster evidence-based practices and promote the development of effective therapeutic interventions. Through its expertise, the center plays a vital role in ensuring the integrity and reliability of clinical research data, ultimately contributing to informed decision-making in healthcare.

Locations

Chicago, Illinois, United States

Chapel Hill, North Carolina, United States

Salt Lake City, Utah, United States

Birmingham, Alabama, United States

Miami, Florida, United States

Detroit, Michigan, United States

New York, New York, United States

Winston Salem, North Carolina, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Providence, Rhode Island, United States

Dallas, Texas, United States

Galveston, Texas, United States

Houston, Texas, United States

Patients applied

0 patients applied

Trial Officials

Dwight Rouse, MD

Principal Investigator

University of Alabama at Birmingham

Menachem Miodovnik

Study Director

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials